Literature DB >> 3384452

Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation.

A E Ahmed1, K Whaley.   

Abstract

A pre-albumin glycoprotein that inhibits complement-mediated prevention of immune precipitation (PIP) has been purified from normal human serum by sequential affinity chromatography on IgG-Sepharose, protein A-Sepharose and Con A-Sepharose. A total of 4.7 mg of this protein were obtained from 50 ml of serum, representing a yield of 49% and a 253-fold degree of purification. We have named this glycoprotein gp60 as it has an apparent molecular weight of 60,000 on SDS-PAGE. The addition of gp60 to normal serum produced dose-dependent inhibition of both PIP and solubilization of immune precipitates. Maximum inhibition of PIP was achieved by a concentration of 600 micrograms/ml. A monospecific antiserum was produced by the immunization of rabbits, which enabled us to develop an enzyme-linked immunosorbent assay to measure serum concentrations of gp60. In 12 normal sera the mean concentration was 205 micrograms/ml (range 132-258 micrograms/ml), while that in 15 rheumatoid arthritis sera was 515 micrograms/ml (range 430-708 micrograms/ml). The serum concentration of this protein correlated with the level of inhibition of PIP (r = 0.91, P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384452      PMCID: PMC1385184     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Inhibition of C1q binding to antigen-antibody complexes by a factor in rheumatoid arthritis serum.

Authors:  I P Niven; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

5.  Complement, the immune-complex lattice, and the pathophysiology of complement-deficiency syndromes.

Authors:  J A Schifferli; D K Peters
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

6.  Prevention of immune precipitation by purified classical pathway complement components.

Authors:  J K Naama; A O Hamilton; A C Yeung-Laiwah; K Whaley
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

7.  Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.

Authors:  J A Schifferli; P Woo; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

8.  Complement-mediated inhibition of immune precipitation in patients with immune complex diseases.

Authors:  J K Naama; W S Mitchell; A Zoma; J Veitch; K Whaley
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

9.  IgM-RF prevents complement-mediated inhibition of immune precipitation.

Authors:  W S Mitchell; J K Naama; J Veitch; K Whaley
Journal:  Immunology       Date:  1984-07       Impact factor: 7.397

10.  Inhibition of complement-mediated solubilisation of antigen-antibody complexes by serum factor(s) in patients with various connective tissue diseases.

Authors:  J Webb; A Zoma; S Cobb; J Veitch; K Whaley
Journal:  Aust N Z J Med       Date:  1986-08
View more
  7 in total

1.  Immunohistochemical and functional studies of glycoprotein 60 (gp60) in platelets.

Authors:  S A Mohamadein; A E Ahmed; M Griffiths; G P Sandilands; N P Lucie; K Whaley
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

2.  The relative roles of C4A and C4B in prevention of immune precipitation, solubilisation and immune adherence.

Authors:  E R Holme; J Veitch; A Johnston; I C McKay; K Whaley
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

3.  Isolation and characterization of a high molecular weight lymphocyte Fc gamma receptor-blocking factor associated with renal allograft survival.

Authors:  G P Sandilands; J E Cocker; M A McMillan; A M Owsianka; H Marsden; B J Junor; J D Briggs; R N MacSween
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

4.  Familial properdin deficiency associated with chronic discoid lupus erythematosus.

Authors:  E R Holme; J Veitch; A Johnston; G Hauptmann; B Uring-Lambert; M Seywright; V Docherty; W N Morley; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis.

Authors:  M M O'Sullivan; N Amos; A Bedwell; B D Williams
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

6.  Deficiency of complement component C3 is associated with accelerated removal of soluble 123I-labelled aggregates of IgG from the circulation.

Authors:  C Halma; M R Daha; J A Camps; J H Evers-Schouten; E K Pauwels; E s Van
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

7.  Recombinant soluble Fc gamma RII inhibits immune complex precipitation.

Authors:  A L Gavin; B D Wines; M S Powell; P M Hogarth
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.